acanthosis nigricans: a brown to black, poorly defined, velvety hyperpigmentation of the skin. It is usually found in body folds, such as the posterior and lateral folds of the neck, the armpits, groin, navel, forehead, and other areas.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
127 |
4. Check minimum number of eventsNone |
127 |
5. Include endpointsNone |
127 |
6. Filter based on genotype QC (FinnGen only) |
117 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L80-L99
- Name in latin
- Acanthosis nigricans
Similar endpoints
↥List of similar endpoints to
Acanthosis nigricans
based on the number of shared cases.
Similar with more cases:
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1289 | 650 | 620 |
| Only index persons | 1001 | 528 | 473 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 35.84 | 38.52 | 32.41 |
| Only index persons | 27.01 | 31.54 | 21.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 117 | 69 | 48 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 28.73 | 32.96 | 22.67 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 127
- Matched controls
- 1270
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L83
ICD-10 Finland
Acanthosis nigricans
+∞
88.0
74
*
70119
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Keratosis, hyperkeratosis alia sive NUD
+∞
32.7
30
*
SPAT1148
SPAT
Treatment of chronic ulcer or burn
5.8
13.3
28
59
70115
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Ichthyosis
+∞
12.7
12
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.3
11.8
22
41
R60.0
ICD-10 Finland
Localized oedema
4.7
9.3
24
60
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
4.6
9.1
24
61
D01AC02
ATC
miconazole; topical
8.7
9.0
19
25
70110
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Keratoderma acquisitum (Kämmen, jalkapohja) (palmare, plantare)
+∞
8.4
8
*
J01FF01
ATC
clindamycin; systemic
3.0
7.7
48
215
J01MA12
ATC
levofloxacin; systemic
3.4
7.6
33
119
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.1
7.5
39
157
L89
ICD-10 Finland
Decubitus ulcer and pressure area
84.8
7.5
8
*
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
32.0
7.2
9
*
E66.9
ICD-10 Finland
Obesity, unspecified
7.9
6.9
15
21
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.9
6.9
22
64
E66.8
ICD-10 Finland
Other obesity
7.6
6.7
15
22
Z01.8
ICD-10 Finland
Other specified special examinations
3.0
6.6
37
155
E000001, ,
ATC
2.9
6.5
38
163
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.0
6.5
34
137
SPAT1262
SPAT
Handing over of treatment supplies
3.4
6.3
26
90
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
31
102
3.70
8.28
10.1
4.0
1.06
0.99
mmol/l
0.78
31
97
72
429
2.57
6.32
9.6
5.1
1.22
1.22
mmol/l
0.06
60
361
10
10
10.73
5.64
1.3
1.2
—
—
—
0
0
8
5
16.93
5.48
1.1
1.0
51.25
43.60
u/l
—
8
5
64
387
2.32
5.12
3.0
2.2
77.57
74.67
nmol/l
0.26
58
348
26
109
2.74
4.51
3.6
1.8
22.78
25.89
%
0.44
21
97
67
450
2.03
3.77
3.3
2.7
135.55
97.09
ug/l
0.85
60
423
60
398
1.96
3.40
11.5
10.2
1.27
1.13
inr
0.60
22
132
40
232
2.06
3.29
4.7
3.6
21.07
8.97
mg/mmol
0.69
33
135
37
213
2.04
3.08
2.3
1.9
3.46
2.85
mg/l
0.92
30
180
28
148
2.14
2.90
1.9
1.6
970.47
1169.56
nmol/l
0.58
23
113
9
23
4.13
2.83
1.1
1.2
—
—
—
0
0
76
572
1.82
2.71
9.1
9.1
4.73
4.00
e9/l
0.93
68
490
27
148
2.05
2.54
1.5
1.8
—
—
—
0
0
6
12
5.19
2.43
2.5
4.1
64.33
61.50
%
—
6
12
5
8
6.45
2.39
1.6
1.1
—
—
—
0
0
27
152
1.99
2.36
3.4
3.0
224.95
72.84
ng/l
0.31
20
100
94
777
1.81
2.23
4.6
3.7
14.41
14.58
pmol/l
0.22
87
707
105
900
1.96
2.19
7.6
4.8
40.29
39.11
mmol/mol
0.61
99
840
35
223
1.79
2.09
3.1
3.1
1608.86
833.57
ng/l
0.75
29
192
6
16
3.88
1.96
2.0
1.9
—
—
—
0
0
47
332
1.66
1.93
4.7
3.0
—
—
—
0
0
9
35
2.69
1.84
1.4
2.0
—
—
—
0
0
9
35
2.69
1.84
1.9
2.3
—
—
—
0
0
9
35
2.69
1.84
1.6
1.7
36.22
39.66
nmol/l
—
9
35
11
48
2.41
1.76
1.5
1.5
—
—
—
0
0
45
322
1.62
1.73
2.5
2.8
2.36
2.35
mmol/l
0.29
37
298
12
56
2.26
1.67
4.8
2.6
94.42
66.83
ng/l
0.75
12
48
8
32
2.60
1.62
1.4
1.4
—
—
—
0
0
7
28
2.58
1.47
8.7
2.3
22.23
25.06
mmol/l
—
7
28
31
211
1.62
1.44
1.6
1.8
0.63
1.04
mg/l
1.11
23
158
83
710
1.49
1.30
4.3
2.8
74.05
44.84
u/l
1.16
76
671
5
18
2.85
1.29
1.4
1.5
—
—
—
0
0
36
261
1.53
1.27
1.3
1.3
0.69
1.10
u/ml
—
7
67
45
343
1.48
1.26
2.3
1.7
88.15
93.42
pmol/l
0.33
28
161
5
112
0.42
1.20
1.4
1.6
—
—
—
0
0
16
97
1.74
1.13
4.4
4.8
105.06
104.14
mmol/l
0.30
16
97
11
60
1.91
1.06
1.7
1.4
—
—
—
0
0
61
506
1.40
1.05
3.8
3.4
0.00
0.01
estimate
—
10
101
61
510
1.38
0.98
3.8
3.5
0.00
0.00
estimate
—
9
92
16
102
1.65
0.96
1.3
1.6
—
—
—
0
0
60
503
1.37
0.94
5.2
4.8
0.00
0.00
estimate
—
10
92
12
71
1.76
0.92
2.9
2.2
5.94
5.66
kpa
0.52
12
71
103
946
1.47
0.90
5.6
4.3
2.10
1.84
mu/l
1.22
97
872
6
29
2.12
0.90
1.0
1.2
—
—
—
0
0
23
163
1.50
0.90
1.4
1.3
19.59
27.12
iu/ml
—
9
52
16
104
1.62
0.90
1.3
1.5
—
—
—
0
0
15
96
1.64
0.89
8.3
7.3
—
—
—
0
0
15
97
1.62
0.86
4.3
3.2
—
—
—
0
0
17
114
1.57
0.85
3.4
3.6
27.45
30.41
%
0.41
11
79
8
47
1.75
0.82
1.0
2.3
0.14
0.09
e6/l
—
8
47
6
34
1.80
0.77
1.0
1.0
—
20.90
—
0
5
9
54
1.72
0.76
1.7
1.2
—
—
—
0
0
21
152
1.46
0.75
1.4
1.3
1.38
8.69
u/ml
—
8
56
7
38
1.89
0.75
3.4
2.6
64.70
48.53
%
—
7
38
86
934
0.75
0.72
24.4
14.1
14.39
14.71
%
0.26
86
921
47
393
1.31
0.71
3.8
3.5
—
—
—
0
0
103
960
1.39
0.70
16.3
11.0
85.83
87.70
ml/min/173m2
0.27
89
765
10
62
1.67
0.67
1.1
1.0
—
—
—
0
0
16
219
0.69
0.65
2.9
3.9
30.48
22.83
%
—
6
83
5
29
1.75
0.64
1.0
1.3
—
—
—
0
0
5
30
1.69
0.62
1.2
2.1
—
—
—
0
0
5
30
1.69
0.62
1.0
1.1
—
—
—
0
0
19
141
1.41
0.61
2.5
2.7
2.58
3.42
e6/l
—
10
75
20
150
1.40
0.60
2.4
2.6
0.62
0.90
e6/l
0.59
11
83
14
193
0.69
0.59
1.9
1.3
—
—
—
0
0
6
39
1.56
0.54
5.0
5.0
25.22
24.48
mmol/l
—
6
39
7
106
0.64
0.51
1.6
1.5
—
—
—
0
0
16
120
1.38
0.49
2.2
1.7
27.43
29.70
s
1.36
16
115
28
231
1.27
0.46
2.1
2.0
—
—
—
0
0
31
263
1.24
0.41
3.7
3.6
0.00
0.00
estimate
—
8
93
32
273
1.23
0.40
3.5
2.7
0.20
0.34
e6/l
0.55
26
200
72
773
0.84
0.39
3.4
3.5
—
—
—
0
0
113
1091
1.32
0.39
22.7
13.2
81.10
73.45
umol/l
0.79
113
1091
53
478
1.19
0.38
3.0
2.4
—
—
—
0
0
6
41
1.49
0.36
3.2
2.0
1.15
1.03
%
—
6
41
6
45
1.35
0.34
6.0
7.2
1.50
1.43
%
—
6
45
6
45
1.35
0.34
6.0
7.2
0.82
0.68
%
—
6
45
114
1169
0.76
0.33
31.7
17.2
40.77
40.42
%
0.25
107
1110
105
1011
1.22
0.32
5.8
4.3
2.75
2.77
mmol/l
0.04
99
948
107
1035
1.21
0.29
22.9
11.7
19.37
22.84
mg/l
0.69
91
786
6
81
0.73
0.25
1.2
1.3
—
—
—
0
0
5
37
1.37
0.24
1.4
1.6
—
—
—
0
0
5
37
1.37
0.24
1.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
23
203
1.16
0.21
1.9
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
27
245
1.13
0.17
2.2
1.7
—
—
—
0
0
21
187
1.15
0.17
1.8
2.2
—
—
—
0
0
5
44
1.14
0.10
2.2
1.5
—
—
—
0
0
33
324
1.03
0.00
3.8
3.9
43.48
32.45
ng/l
0.31
20
205
11
114
0.96
0.00
3.1
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
99
990
1.00
-0.00
6.4
3.9
6.08
5.81
mmol/l
1.00
93
920
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
14.23
—
0
5
9
95
0.94
-0.00
3.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
176.50
—
0
6
0
5
0.00
-0.00
0.0
1.8
—
35.44
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
52
0.96
-0.00
1.8
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_ACANTHNIGRICANS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ACANTHNIGRICANS | 1.857 [1.28, 2.7] | 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.827 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 312 females with L12_ACANTHNIGRICANS died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have L12_ACANTHNIGRICANS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.187% | No data |
| 5 | 1.092% | No data |
| 10 | 2.893% | No data |
| 15 | 5.937% | No data |
| 20 | 10.56% | No data |
Relationships between endpoints
↥Index endpoint: L12_ACANTHNIGRICANS – Acanthosis nigricans
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data